

**Maryland Board of Pharmacy
Public Board Meeting**

**Agenda
August 19, 2026**

Board Committee	Title	Present	Absent
Banks, B.	Consumer Representative		
Cundiff, J.	Independent Representative		
De Leon, M.	Acute Care Hospital Representative		
Geigher, P.	Consumer Representative / Vice President		
LeGallee, W.	Long Term Care Representative		
Masood, A.	Chain Drug Store Representative		
Oriaifo, A.	At-Large Representative		
Patel, A.	Chain Drug Store Representative / President		
Robinson, D.	Pharmacy Technician Representative		
Shepardson, A.	Home Infusion Representative		
Shimoda, M.	At-Large Representative		
Slagle, K.	Independent Representative		
Vazquez, J.	Hospital Acute Care Representative / Secretary		
Board Counsel			
Bethman, L.	Board Counsel		
Felter, B.	Board Counsel		
Board Staff			
Speights-Napata, D.	Executive Director		
Partin, J.	Director IT, Budget and Procurement		
Valerio, L.	Licensing Manager		
Leak, T.	Compliance Director		
Gaskins, J.	Legislative Liaison		
Watts-Vess, S.	Communications Manager		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
---------	-------------------	------------	-------------------------------	---------

I. Executive Committee Report(s)	A.) A. Patel, Board President	<i>Members of the Board with a conflict of interest relating to any item on the agenda are advised to notify the Board at this time or when the issue is addressed in the agenda.</i> 1. Call to Order – 2. Sign-in Introduction and of meeting attendees – <i>(Please indicate on sign-in sheet if you are requesting CE Units for attendance)</i> 3. Distribution of Agenda and packet materials. 4. Review and approve July Public Meeting Minutes.		
---	--------------------------------------	--	--	--

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
II. A. Executive Director Report	D. Speights-Napata, Executive Director	1. Staff Updates 2. Meeting Update		1. 2.

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results										
B. New Business	A. Patel, Board President													
C. Operations Report	J. Partin, Director IT, Budget and Procurement	1. Procurement and Budget Updates 2. Management Information Systems (MIS) Unit Updates												
D. Licensing	K. Slagle, Chair	1. Unit Updates 2. Monthly Statistics <table><tr><td>License Type</td><td>New</td><td>Renewed</td><td>Reinstated</td><td>Total</td></tr><tr><td>Distributor</td><td>13</td><td>0</td><td>0</td><td>1,653</td></tr></table>	License Type	New	Renewed	Reinstated	Total	Distributor	13	0	0	1,653		
License Type	New	Renewed	Reinstated	Total										
Distributor	13	0	0	1,653										

Subject	Responsible Party	Discussion					Action Due Date (Assigned to)	Results
---------	-------------------	------------	--	--	--	--	-------------------------------	---------

			Pharmacy	17	1	5	2,193			
			Pharmacist	75	539	2	13,063			
			Vaccination	76	266	0	6,661			
			Pharmacy Intern - Graduate	0	0	0	38			
			Pharmacy Intern - Student	24	10	0	422			
			Pharmacy Technician	143	437	5	11,631			
			Pharmacy Technician-Student	0	0	0	35			
			TOTAL	348	1,253	12	35,696			

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
---------	-------------------	------------	-------------------------------	---------

E. Compliance	T. Leak, Compliance Director	• Unit Updates • Monthly Statistics Complaints & Investigations: New Complaints – 50 • Customer Service - 7 • Employee Pilferage - 2 • Licensing Referral - 2 • Inspections - 21 • Medication Error - 4 • Refusal to Fill- 1 • Out of State Disciplinary Actions- 10 • Unauthorized Personnel - 2 • Miscellaneous - 1 Resolved - 33 Actions within Goal - 33 Formal Disciplinary Actions Taken - 9 Summary Actions voted on- 2 Average Days to Complete - 93 Regulatory Inspections: Total - 79 Annual Inspections - 67 • Chain - 17 • Independent - 18 • Sterile Compounding - 6 • Repository - 9 • Comprehensive Care - 3 • Hospital - 2 • Supplemental Assisted Living - 4		
---------------	------------------------------------	---	--	--

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		- Follow up - 1 - Distributor - 6 - Attempted- 1 Openings -6 Remodels -4 Sterile Relocations - 0 Relocations – 1 Repository Openings -0 Closing Inspections - 1 Change of Ownership - 0 Pending Opening – 0 Pending Closing - 1		
F. Legislation & Regulations	J. Gaskins, Legislative Liaison	<u>Legislation</u> <u>Regulations</u>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
---------	-------------------	------------	-------------------------------	---------

III. Committee Reports A. Practice Committee	M. Shimoda, Chair	<u>QUESTION ONE: K.B.</u> We would appreciate any clarification the Board can provide regarding its current position. Specifically: • Is an Immediate Supervisor now required for all wholesale distributor licensees? • If yes, will there be any official communication of this change? • Does this requirement apply only to new license applications, or does it also apply to currently licensed wholesale distributors? • If it applies to existing licensees, what is the process for updating a license to add an Immediate Supervisor? • If it applies to existing licensees, is there a compliance deadline for submitting this information? We appreciate any direction you can provide and will communicate the Board's guidance accordingly. Thank you for your time and assistance. We look forward to your response. <u>QUESTION ONE RESPONSE:</u> Thank you for your inquiry. The Maryland Pharmacy Act requires that a wholesale distributor have both a designated representative and immediate supervisor. The only exception to this requirement is if a distributor has only one employee. The Board will monitor compliance on initial and renewal applications and inspections. Should you have additional questions, please consult with your General Counsel.		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
	Commissioners Adrienne Shepardson and Javier Vazquez are Recused	<u>Drug Therapy Management Programs</u> <u>Pharmacy:</u> Johns Hopkins <u>Pharmacists:</u> Traci Grucz & Stephanie Seto <u>Request:</u> Physician - Pharmacist Update		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
---------	-------------------	------------	-------------------------------	---------

B. Licensing Committee	K. Slagle, Chair	1. Review of Pharmacist New Applications: a. C.N. - The applicant recently passed the UMPJE and is currently awaiting completion of the MD Competency Assessment Module. The applicant requests an extension of the NAPLEX score, which expired on July 19, 2026. <u><i>Committee Recommendation: Approve. The extension of the NAPLEX score is granted for three months (until November 30, 2026).</i></u> 2. Review of Pharmacist Renewal Applications: None 3. Review of Pharmacist Reinstatement Applications: None 4. Review of Technician New Applications: b. D.C. - The trainee is requesting an extension to complete the CVS Pharmacy Technician Training Program due to the demands of attending college, which limited his availability to work. Additionally, after completing his college finals and becoming available to work additional hours, sufficient work hours were not available for him to continue progressing through the program. To date, the trainee has completed 114 hours of the required training. <u><i>Committee Recommendation: Approve. An extension is granted through September 30, 2026. CVS must submit written documentation verifying the number of on-the-job training hours the trainee has completed. If CVS is willing to accommodate the trainee by providing the remaining hours necessary to complete the required 160 hours, the Board has no objection to the trainee completing those hours by September 30, 2026. Upon completion of the required training hours,</i></u>		
------------------------	------------------	--	--	--

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
---------	-------------------	------------	-------------------------------	---------

		<u>the trainee must immediately cease practicing pharmacy until a registration has been issued by the Board.</u> 5. Review of Technician Renewal Applications: None 6. Review of Technician Reinstatement Applications: None 7. Review of Intern New Applications: None 8. Review of Intern Renewal Applications: c. A.D. - The registrant (Intern-Grad) is requesting an extension of the Intern registration, which expired in April 2026, to allow him to continue working while completing the licensure process. The registrant is currently preparing to take the pharmacist licensure examination and anticipates obtaining a pharmacist license within the next few months. <u>Committee Recommendation: Deny. The maximum allowable period for practice under a pharmacist intern registration has been reached. The individual may apply for registration as a pharmacy technician if they satisfy all applicable eligibility criteria and application requirements.</u> 9. Review of Pharmacy New Applications: None 10. Review of Pharmacy Renewal Applications: None 11. Review of Pharmacy Reinstatement Applications: None 12. Review of Distributor New Applications: None 13. Review of Distributor Renewal Applications: None 14. Review of Distributor Reinstatement Applications: d. S.P.L - The wholesale distributor is requesting a refund of the reinstatement fee. The establishment stated that it ceased operations in Maryland in 2021 by		
--	--	--	--	--

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
---------	-------------------	------------	-------------------------------	---------

		formally requesting withdrawal of its permit and argued that the Board's regulations do not address permits that have been voluntarily withdrawn and closed before their expiration date. The establishment further contended that requiring payment of the reinstatement fee imposes a substantially greater financial burden than would apply to submitting an initial application. <u>Committee Recommendation: Deny. The Board considers a voluntarily withdrawn permit to be equivalent to an expired permit. Accordingly, if the establishment previously held a permit, it must reinstate that permit prior to resuming operations.</u> 15. Review of Continuing Education Program Request: None 16. Review of Pharmacy Technician Training Program: e. Parkland Pharmacy - <u>Committee Recommendation: Approve.</u> f. CareCompass Pharmacy Technician Training Program - <u>Committee Recommendation: Approve.</u> g. Healthwise Pharmacy - <u>Committee Recommendation: Approve.</u> h. PSG of MD Pharmacy Technician Training Program (using PEER) - <u>Committee Recommendation: Approve.</u> 17. New Business:		
--	--	---	--	--

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
---------	-------------------	------------	-------------------------------	---------

		i. J.P. - The Walgreens Pharmacy Technician Training Program was approved by the Maryland Board in 2020. At that time, the curriculum and supporting program materials were submitted and approved; however, the Walgreens ASHP final examination was not specifically submitted for review. As a result, Walgreens has continued utilizing the Maryland-specific examination while also requiring completion of the Walgreens ASHP final examination. Our request is for the Board to review and approve the examination component associated with this already-approved training program. Historically, Walgreens has utilized a Maryland-specific examination to satisfy Maryland requirements. As a result, pharmacy technician trainees in Maryland currently complete two separate examinations: the Maryland-specific examination and the Walgreens ASHP final examination. The Walgreens ASHP final examination is already administered to Maryland trainees, and successful completion of both examinations is currently required. Maryland is the only state in which Walgreens requires trainees to complete two separate final examinations. The Walgreens ASHP final examination is the standard assessment utilized throughout the country in conjunction with our ASHP-accredited technician training program. It is specifically designed to assess competency across the approved curriculum and to prepare technician trainees for national certification examinations, including the PTCB and ExCPT (NHA) examinations. Successful completion of the Walgreens ASHP final examination is required for participants to receive a certificate of completion from the training program. Because the Walgreens Pharmacy Technician Training Program has already been approved by the Maryland Board, we respectfully request that the		
--	--	--	--	--

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		Board review and approve the Walgreens ASHP final examination as the examination associated with the Walgreens Pharmacy Technician Training Program previously approved by the Maryland Board in 2020. Approval of the ASHP final examination would align Maryland with the process utilized throughout the rest of the country while maintaining a rigorous assessment of technician competency and readiness for national certification. <u>Committee Recommendation:</u> <i>Approve. The training program must update its documents to clearly specify that participants are required to achieve a minimum passing score of 75% or higher on the examination as a condition of successful completion of the program.</i>		
C. Public Relations Committee	J. Vázquez, Chair	Public Relations Committee Update:		.
D. Disciplinary	M. DeLeon, Chair	Disciplinary Committee Update:		
E. Emergency Preparedness Task Force	A. Patel, Board President	Emergency Preparedness Task Force Update:		
IV. Other Business & FYI	A. Patel, Board President			
V. Adjournment	A. Patel, Board President	A. The Public Meeting was adjourned – B. I would like to ask for a motion to close the public meeting and open a closed public session for the purpose of engaging in medical review committee deliberations of confidential		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
---------	-------------------	------------	----------------------------------	---------

		matters contained in licensure applications in accordance with General Provisions Article Section 3-305(b)(13). C. Immediately thereafter, J. Vazquez convened an Administrative Session for purposes of discussing confidential disciplinary cases. D. With the exception of cases requiring recusals, the Board members present at the Public Meeting continued to participate in the Administrative Sess		
--	--	---	--	--